BioCentury | Mar 17, 2021
Deals

March 17 Quick Takes: Merck-Amathus enter neurodegenerative disease collaboration; plus WuXi, Sana-Fujifilm, Rubius, Inflammatix, StrideBio and more

...Phase Ib/II trial of XVR011 to treat COVID-19. VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures, SRIW, Noshaq...
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...company Imcyse S.A. raised EUR 21.3 million ($25.8 million) from existing investors Biogenosis, Epimede, LSP, Noshaq...
BioCentury | May 5, 2020
Finance

May 4 Quick Takes: Following Lyra’s success, Ayala readies for NASDAQ IPO; plus Medable and Hyloris

...play Hyloris Pharmaceuticals SA raised EUR15 million ($16.4 million) in a funding round from Scorpiaux, Noshaq...
BioCentury | Jan 23, 2020
Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

...Shinhan-Cognitive Start-up Fund, UTC 2019 Bioventurefund, SRIW and Sambrinvest. Also participating were existing investors SFPI-FPIM, Noshaq...
BioCentury | Jul 12, 2019
Financial News

July 11 Financial Quick Takes: Illumina tumbles on revenue miss; plus PureTech, Horizon and more

...in preclinical development to treat influenza A and B strains. The round was led by Noshaq...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

...SRIW) and Belgium’s Federal Holding and Investment Company (SFPI), as well as prior investors Biogenosis, Noshaq...
Items per page:
1 - 6 of 6
BioCentury | Mar 17, 2021
Deals

March 17 Quick Takes: Merck-Amathus enter neurodegenerative disease collaboration; plus WuXi, Sana-Fujifilm, Rubius, Inflammatix, StrideBio and more

...Phase Ib/II trial of XVR011 to treat COVID-19. VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures, SRIW, Noshaq...
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...company Imcyse S.A. raised EUR 21.3 million ($25.8 million) from existing investors Biogenosis, Epimede, LSP, Noshaq...
BioCentury | May 5, 2020
Finance

May 4 Quick Takes: Following Lyra’s success, Ayala readies for NASDAQ IPO; plus Medable and Hyloris

...play Hyloris Pharmaceuticals SA raised EUR15 million ($16.4 million) in a funding round from Scorpiaux, Noshaq...
BioCentury | Jan 23, 2020
Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

...Shinhan-Cognitive Start-up Fund, UTC 2019 Bioventurefund, SRIW and Sambrinvest. Also participating were existing investors SFPI-FPIM, Noshaq...
BioCentury | Jul 12, 2019
Financial News

July 11 Financial Quick Takes: Illumina tumbles on revenue miss; plus PureTech, Horizon and more

...in preclinical development to treat influenza A and B strains. The round was led by Noshaq...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

...SRIW) and Belgium’s Federal Holding and Investment Company (SFPI), as well as prior investors Biogenosis, Noshaq...
Items per page:
1 - 6 of 6